GE Revises Instrumentarium Buy-Out Date In Face Of Anti-Trust Scrutiny
This article was originally published in The Gray Sheet
Executive Summary
GE Medical Systems' decision to extend the timing of its tender offer for Instrumentarium suggests the company may be forced to divest some critical care or imaging assets in order for the merger to earn European and U.S. anti-trust approval
You may also be interested in...
GEMS Wraps Up OR Holiday Wish List With $2 Bil. Instrumentarium Buy
GE Medical Systems plans to grow Instrumentarium's business in excess of 20% over the next several years following its $2.06 bil. acquisition of the Finnish firm
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.